Both classes share the same primary side effects (nausea, occasional vomiting, constipation, reflux, fatigue in the early weeks)
[1] Administration Instructions Intramuscular Injection Instructions 503A vs 503B 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider
Affiliate Disclosure This website may earn commissions from links to FDA-approved medications, telehealth providers, and related health services
For starters, the focus on cardiovascular outcomes trials (CVOTs) and the accompanying excellent results have elevated the profile of GLP-1 agonists, making them more appealing to healthcare practitioners looking for complete diabetes management
A comparison of preferences for two GLP-1 productsliraglutide and exenatidefor the treatment of type 2 diabetes
the combination also increased the cAMP response produced by growth hormone-releasing factor alone